This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.
This is an interventional, open label, trial of definitive hypofractionated radiotherapy for patients with locally advanced pancreatic cancer. Within this study radiotherapy shall be delivered with active scanning particle-therapy using proton- or carbon ions radiotherapy. Particle therapy will be performed with a simultaneous integrated boost (SIB) treating a larger target volume, including elective lymph node stations and neural plexus, at a lower dose and boosting macroscopic disease. The investigator will explore the efficacy of these treatment in a real world scenario in which patients are allowed to receive standard systemic treatment and standard surgical treatment (if conversion to resectability is achieved). However, and in order to record and to gain better understanding of the influence of systemic therapies on the outcomes parameters of this study, patients will be sub-stratified in 3 groups: i) patients receiving FOLFIRINOX, ii) patients receiving Gemcitabine + Nanoparticle Albumin Bound Paclitaxel (NAB-Paclitaxel), iii) patients receiving other systemic therapies or not receiving antineoplastic systemic therapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
30
According to the radiation plan (between 25 and a maximum of 40 Gy). Planning Target Volume 1 : 25 Gy (Relative Biological Effectiveness) in 5 fractions of 5 Gy (Relative Biological Effectiveness) Planning Target Volume 2 : A simultaneous integrated boost (SIB) will be delivered to the Planning Target Volume 2: 40 Gy (Relative Biological Effectiveness) in 5 fractions of 8 Gy (Relative Biological Effectiveness).
Evaluation before treatment-start, after treatment and follow-up period.
For treatment planning as well as for follow-up radiological tumor assessment.
EBG MedAustron GmbH
Wiener Neustadt, Lower Austria, Austria
RECRUITINGLocoregional tumor control
Rate of locoregional tumor control at two year will be evaluated radiologically. This endpoint will be measured with the actuarial approach.
Time frame: At two year
Loco-regional progression-free survival
This endpoint will be measured with the actuarial approach. It will be assessed as the union of locoregional control and survival. Patient with loco regional recurrence will be considered failures. Deceased patient will also be considered failures. Patient lost to follow-up without evidence of locoregional recurrence will be censored. Distant metastasis and peritoneal carcinosis will be irrelevant respect to this endpoint.
Time frame: 104 weeks after therapy
Overall survival
This endpoint will be measured with the actuarial approach. All deaths will be considered failures, patient lost to follow-up will be censored.
Time frame: Maximal 109 weeks
Incidence of CTCAE v5.0 G4-5 toxicity
This endpoint will be scored as gross rate. The investigator will measure the number of patients experiencing at least one toxicity \>= Grade 4 and \>= Grade 5 and the number of events \>= Grade 4 and \>= Grade 5. The crude number will be divided by the total number of patients treated.
Time frame: From enrollment to six months after radiation therapy initiation
Patient reported Health-related Quality of Life, measured with Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)
Quality of life will be measured with Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) before radiation therapy and at each follow-up. The FACT-Hep has 27 (+ a subscale with 18 additional) questions, each of which is answered using a 5-point Likert scale ranging from 0 (Not at all) to 4 (Very much). Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored. Questions measure the respondents' health state over the last 7 days in four subscales: Physical Well-Being (7 questions), Social/Family Well-Being (7 questions), Emotional Well-Being (6 questions), and Functional Well-being (7 questions). This disease-specific version of the FACT-Hep contain these four core subscales, with additional (18) questions appended to address disease-specific factors. The higher the score the better the Quality of Life.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
For treatment planning as well as for follow-up radiological tumor assessment.
For treatment planning as well as for follow-up radiological tumor assessment.
Time frame: Maximal 109 weeks
Patient reported Health-related Quality of Life, measured with European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-C30
Quality of life will be measured with EORTC Quality of Life Questionnaire-C30 before radiation therapy and at each follow-up. Questionnaire developed to assess the quality of life of cancer patients. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / quality of life (QoL) represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: Maximal 109 weeks
Patient reported Health-related Quality of Life, measured with Brief Pain Inventory
Quality of life will be measured with Brief Pain Inventory before radiation therapy and at each follow-up. The Brief Pain Inventory (BPI) is a measurement tool for assessing clinical pain.The interference items were now presented with 0-10 scales, with 0=no interference and 10=interferes completely.
Time frame: Maximal 109 weeks
Incidence of CTCAE v5.0 Grade 2 - Grade 5 acute, subacute and late toxicities
The number of events, their grade and their time course will be measured.
Time frame: 104 weeks after therapy